Next Article in Journal
Staphylococcus capitis: Review of Its Role in Infections and Outbreaks
Next Article in Special Issue
Study of Essential Oil Isolated from Achiote (Bixa orellana) Leaves: Chemical Composition, Enantiomeric Distribution and Antimicrobial, Antioxidant and Anticholinesterase Activities
Previous Article in Journal
Rapid Screening and Comparison of Chimeric Lysins for Antibacterial Activity against Staphylococcus aureus Strains
Previous Article in Special Issue
Antibacterial and Antibiofilm Activities of β-Lapachone by Modulating the Catalase Enzyme
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Antibiotics
Volume 12
Issue 4
10.3390/antibiotics12040668
antibiotics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Antifungal and Antibiofilm Activity of Colombian Essential Oils against Different Candida Strains

by
Jennifer Ruiz-Duran
1,
Rodrigo Torres
2,
Elena E. Stashenko
3 and
Claudia Ortiz
1,*
1
Escuela de Microbiología y Bioanálisis, Universidad Industrial de Santander, Bucaramanga 680002, Colombia
2
Grupo de Investigación en Bioquímica y Microbiología, Bucaramanga 680002, Colombia
3
Centro de Cromatografía y Espectrometría de Masas, CROM-MASS, Escuela de Química, Universidad Industrial de Santander, Bucaramanga 680002, Colombia
*
Author to whom correspondence should be addressed.
Antibiotics 2023, 12(4), 668; https://doi.org/10.3390/antibiotics12040668
Submission received: 23 February 2023 / Revised: 20 March 2023 / Accepted: 27 March 2023 / Published: 29 March 2023
(This article belongs to the Special Issue Antimicrobial and Anti-inflammatory Activity of Bioactive Compounds Extracted from Plants)
Browse Figures
Review Reports Versions Notes

Abstract

:
Most Candida species are opportunistic pathogens with the ability to form biofilms, which increases their resistance to antifungal drug therapies and the host immune response. Essential oils (EOs) are an alternative for developing new antimicrobial drugs, due to their broad effect on cellular viability, cell communication, and metabolism. In this work, we evaluated the antifungal and antibiofilm potential of fifty EOs on C. albicans ATCC 10231, C. parapsilosis ATCC 22019, and Candida auris CDC B11903. The EOs’ antifungal activity was measured by means of a broth microdilution technique to determine the minimum inhibitory and fungicidal concentrations (MICs/MFCs) against the different Candida spp. strains. The effects on biofilm formation were determined by a crystal violet assay using 96-well round-bottom microplates incubated for 48 h at 35 °C. The EOs from Lippia alba (Verbenaceae family) carvone-limonene chemotype and L. origanoides exhibited the highest antifungal activity against C. auris. The L. origanoides EOs also presented antifungal and antibiofilm activity against all three Candida spp., thus representing a promising alternative for developing new antifungal products focused on yeast infections, especially those related to biofilm formation, virulence factors, and antimicrobial resistance.

1. Introduction

Candida spp. are opportunistic pathogens that pose a major threat to immunosuppressed and susceptible patients causing systemic infections with high mortality rates. The most common cause of severe and superficial fungal infections is C. albicans, followed by C. auris, C. glabrata, and C. parapsilosis [1]. In recent years, antifungal resistance has become an increasing problem, with approximately 7% of all Candida spp. bloodstream infections being resistant to drugs used for medical treatment [2,3]. Recently, the WHO published the fungal priority pathogen list to guide research, development, and public health action. This list includes C. auris; C. albicans as critical priority fungi; and C. glabrata, C. tropicalis, and C. parapsilosis as high priority due to their pathogenicity and drug resistance [4].
Candida strains are able to adhere to mucosal and synthetic surfaces forming highly complex structures called biofilms. Biofilms represent an important virulence factor that increases mortality rates, antifungal therapy costs, and length of hospital stays in affected patients [5,6]. These biofilms display increased resistance to environmental factors, the host immune response, and currently available antifungal drug classes. Some studies suggest that Candida spp. can alternate between two modes of cell growth, planktonic and sessile lifestyles, allowing them to thrive in multiple environments avoiding conventional fungal therapies and host defenses [7]. Currently, conventional antifungal drugs have lost efficiency against Candida biofilms and have shown some limitations related to their high toxicity and costs. Another virulence factor related to biofilm formation and cell adhesion is the morphological transition in C. albicans to hyphal structures. The hyphal form of C. albicans is resistant to phagocytosis and facilitates colonization, adhesion, and cell penetration [8,9]. Therefore, hyphal formation is essential for invasion, immune evasion, and biofilm formation, making it an important target for new antimicrobial compounds.
Thus, there has been an increasing interest in the search for new antimicrobial compounds with antibiofilm activity. Among these, natural compounds (e.g., essential oils, EOs) derived from different plants and their secondary metabolites have been identified as promising bioactive molecules because of their biological activities ranging from anti-fungal activity to antivirulence properties [10,11,12]. Plant-derived EOs are a mixture of large and diverse secondary metabolites obtained from plants with interesting biological properties [13,14,15]. For this reason, EOs from tropical and Colombian plants have been evaluated for their antimicrobial activity against planktonic and sessile microorganisms [11,16,17]. Previous studies have demonstrated that some EOs could exhibit several antimicrobial activities, such as antibiofilm, antifungal, and antibacterial activities [18,19,20,21,22]. In this work, we evaluated the antimicrobial potential of 50 EOs from Colombian plants against C. albicans ATCC 10231, C. parapsilosis ATCC 22019, and Candida auris CDC B11903 to identify promising plants and their secondary metabolic compounds with both potential antibiofilm and antifungal activities.

2. Results

2.1. Essential Oils

Fifty EOs were obtained from different plants and chemically characterized by GC/MS (Supplementary Data Tables S1 and S2). Information on the plants and chemical composition of the EOs with high biological (antifungal or antibiofilm) activity against Candida strains are shown in Table 1.

2.2. Determination of Antifungal Activity

To identify EOs with antifungal activity, 50 EOs were initially screened against planktonic C. albicans ATCC 10231, C. auris CDC B11903, and C. parapsilosis ATCC 22019 at a final concentration of 750 µg/mL (Figure 1). The EOs with inhibition over 50% were considered for further testing to determine the MIC50 values. Antifungal activities were highly correlated to plant species and chemical compositions. For EOs with antifungal activity, the MIC and MFC values were also determined (Table 2). Thirteen EOs showed relevant activity against Candida strains. The highest antifungal activity was presented by the EO LACL from Lippia alba, carvone-limonene chemotype against C. auris. Additionally, the EOs derived from L. origanoides plants (LOC, LOCpT, LOT-I, LOTC, and LOT-II) showed inhibitory activity against all of the studied strains. Spearman’s correlation (r2) between the EOs’ constituents and the antifungal activity (Table S5) indicates that compounds like thymol, thymyl methyl ether, carvacrol, γ-terpinene, and p-cymene have a negative correlation, which means that a higher concentration of the compound would probably result in lower MICs/MBICs, thus better antimicrobial activity.

2.3. Effect on Biofilm Formation

Initially, all of the EOs were evaluated at sub-inhibitory concentrations corresponding to their MIC50 values (Supplementary data Table S3). Results indicated that subinhibitory concentrations of L. origanoides EOs (90–188 µg/mL) diminished fungal adhesion in all three strains evaluated. Minimum biofilm inhibitory concentration (MBIC50) values are presented in Table 3 and Table S4. It is important to highlight that EOs with antibiofilm activity were predominantly derived from L. origanoides plants (Figure 2; Table 3).
Spearman’s correlation (r2) between the EOs’ constituents and antibiofilm activity (Table S6) showed that thymol, thymyl methyl ether, carvacrol, and γ-terpinene presented a higher correlation to the inhibition of biofilm formation, in addition to their antifungal potential in planktonic cultures. Additionally, trans-β-bergamotene, cis-β-ocimene, humulene epoxide II, and terpinen-4-ol were mainly related to antibiofilm activity, while iso-menthone was correlated to antibiofilm activity exclusively for C. auris.

2.4. Scanning Electron Microscope (SEM) Analysis

The SEM analysis allowed us to visualize biofilm formation in C. auris after growing for 24 h with and without EO treatments (Figure 3). Subinhibitory concentrations of EO LOT-I (Figure 3B) and LOT-II (Figure 3C) showed significant decreases in cellular adhesion to the glass surface. These results agreed with the inhibition biofilm assays shown above (Figure 2).

2.5. Inhibition of Hyphal Formation in C. albicans

The microscopic observation of C. albicans treated with bioactive EOs showed inhibition hyphal formation at subinhibitory concentrations for the L. origanoides EOs (LOT-I, LOTC, and LOT-II) and Minthostachys mollis (MM-II) (Figure 4). The EOs from L. origanoides inhibited hyphal formation in C. albicans compared to the control group, evidenced by the marked decrease of yeast cells with hyphal morphology. The EO LACL presented a slight inhibition of hyphal formation because only a decrease in hyphal length was observed, but not in the number of hyphae in yeast cells. Cells with hyphae and pseudo hyphae formation tended to aggregate in clusters, while those with inhibition were prone to remain in a planktonic state dispersed in liquid culture.

3. Discussion

The number of infections caused by Candida species has been rising since the 1970s, probably related to the increase in susceptible patients with immunosuppressive therapies, improved diagnosis, and failure of antifungal therapies [23,24]. Generally, drugs used to treat Candida infections are poorly effective against biofilms, triggering the development of antifungal resistance [25]. This has led to the search for new molecules that can improve antifungal therapies through the inhibition of planktonic growth, adhesion, biofilm formation, and other virulence factors such as hyphae production by Candida species [26,27,28,29,30].
Essential oils represent an important source of bioactive compounds with a great variety of biological properties ranging from microbiocide activities to bacteriostatic/fungistatic, or antivirulence effects [16,17,31,32,33]. Previous studies from our lab and collaborators have demonstrated the potential use of EOs derived from Colombian plants for the control of growth and biofilm formation of pathogenic bacteria such as E. coli, S. epidermidis, and methicillin-resistant S. aureus (MRSA) [18,19,20].
In this study, we evaluated the effects of 50 Colombian EOs, by assessing their increased potential in planktonic growth control, biofilm formation, and inhibition of hyphal production in some Candida species. Many EOs reported in the literature have antifungal activity values greater than 1 mg/mL, which can be considered high depending on the cytotoxicity of the EO [34]. In this study, a concentration of 750 µg of EO/mL was used as the cutoff point for antifungal activity, since a highly active EO should exhibit an MIC50 lower than 375 µg/mL [35]. The L. origanoides EOs (LOC, LOCpT, LOT-I, LOTC, and LOT-II) were able to control fungal pathogens at concentrations from 288–750 µg/mL (Table 2). Even though these EOs were obtained from the same plant species and displayed similar antifungal activity, the EOs have different concentrations of their main secondary metabolites. This suggests that the antifungal activity was strongly related to the synergy between the different minor components, rather than to a few major components. However, EOs from L. origanoides thymol chemotypes (LOT-I and LOT-II) presented the highest inhibitory activity in planktonic cultures with MIC50 values of 141–281 µg/mL after 48 h of treatment. Higher concentrations of each bioactive EO were necessary to achieve the MFC. LOT-II presented the best fungicide activity, killing more than 99.9% of the viable cells at 563 µg/mL, probably due to the effect of thymol, which is a well-known microbiocide. C. auris presented lower MFCs for the EOs LOTC, LOT-I, LOT-II, and LACL than for the other two species.
Spearman’s test for antifungal activities (Table S5) demonstrates a moderate correlation for thymol, thymyl methyl ether, carvacrol, γ-terpinene, and p-Cymene with general antifungal activity, consistent with the description of their antimicrobial properties in the literature [36,37]. Thymol is the main compound in LOT-I (75.3%), LOTC (49.4%), and LOT-II (71.7%), and it is probably responsible for the fungistatic and fungicide activities of these EOs. Additionally, thymol is a phenolic monoterpene widely reported in the literature with biological activities against bacteria and fungi, due to its ability to interact with cell membrane components, causing instability and integrity loss of the microbial cell [38,39,40]. Other major compounds of these bioactive EOs were p-cymene, carvacrol, trans-β-caryophyllene, and thymol methyl ether. These components have been reported as bioactive components, but have not been well characterized in terms of antifungal and antibiofilm activity against Candida species [39,40,41,42,43]. Further experiments are needed to identify the possible mechanisms of action of each major compound in fungal pathogens, such as Candida spp.
Additionally, the EOs obtained from the other species of Lippia presented antifungal activity against at least one Candida strain. It is important to highlight that antifungal activity with LACL against C. auris was obtained at low concentrations (MIC50 188 µg/mL), but was less active against the other two Candida strains (MIC50 750 µg/mL). This could be related to the metabolite composition of LACL, which contains a high concentration of limonene, carvone, and germacrene D. Further studies are necessary to identify the possible action mechanisms, the compound synergy, and the metabolic target that make these EOs highly active against C. auris. Zapata et al. also evaluated different L. origanoides chemotypes against clinical and reference strains of Candida, obtaining similar inhibition results [21].
Biofilm formation is a key attribute of the pathogenic traits of the Candida species which is becoming a major problem in clinical settings due to its rapid emergence and high antifungal resistance [26,27]. It has been estimated that most clinical and environmental isolates of Candida are related to biofilm structures [28]. Currently, the available antifungals present reduced effectivity against biofilms due to the presence of extracellular polymeric substances, high cellular density, decreased metabolism, and the presence of persistent cells [3,28]. For this reason, the search for new molecules and compounds with the capacity to prevent biofilm formation, which can be used as preventive agents or adjuvants to conventional strategies, is needed. The inoculum for biofilm formation evaluation was 100-times higher than those used for antimicrobial activity. Therefore, the inhibition percentage of planktonic cells in this assay may be lower at the same concentration.
The EOs from L. origanoides showed the highest inhibitory activity against all strains (MBIC50 53–141 µg/mL) indicating a possible effect on the cell attachment and biofilm formation of Candida species. In this case, LOT-I presented a better biofilm inhibitory activity (MBIC50 53 µg/mL) than LOT-II (MBIC50 94–141 µg/mL). This difference could be attributed to an effect between the different metabolites of this EO that are not present in LOT-II (thymyl acetate and trans-β-bergamotene). Spearman’s correlation test identified that secondary metabolites, such as carvacrol, thymol, and thymyl methyl ether, had a strong correlation to biofilm inhibition; γ-Terpinene, p-cymene, trans-β-Bergamotene, cis-β-ocimene, humulene epoxide II, terpinen-4-ol, and carvacryl acetate presented a moderate/weak correlation to biofilm inhibition (Table S6). These represent an opportunity for future research on biofilm formation and control in Candida species to determine the MICs, synergistic capacities, and action mechanisms.
The inhibition of C. auris biofilm formation in the presence of LOT-I and LOT-II was confirmed by SEM imaging (Figure 3). These results showed a decrease in the number of cells adhered to the surface without visible effects on the integrity of the cells. Surprisingly, the MM-II EO from M. mollis inhibits the adhesion and the concomitant biofilm formation exclusively on the C. auris strain. However, the molecular processes involved in C. auris biofilm formation has not yet been fully described, making it difficult to identify possible relationships between the main compounds of MM-II and biofilm formation. Secondary metabolites of MM-II EO, iso-menthone and menthone, were moderately correlated to antibiofilm activity exclusively against the C. auris strain. Moreover, other authors have evaluated the ability of EOs to inhibit or control the planktonic and sessile growth of C. auris with promising results [11,44,45,46,47]. However, most of those EOs (cinnamon, lemongrass, tea tree, cajeput, Niaouli, and White thyme) showed higher MICs (>375 µg/mL or >0.05% v/v) than those of our bioactive EOs [45,47].
C. albicans can form hyphae structures, which are indicators of pathogenicity and strongly related to biofilm formation [8,48]. New approaches have sought to find molecules that allow for the regulation of this virulence factor with the aim of controlling their pathogenesis [30,33,48,49]. According to the results from the inhibition of biofilm formation, EOs from L. origanoides inhibited hyphal formation at concentrations lower than 94 µg/mL (Figure 4). The formation of hyphal structures is closely related to the biofilm formation of C. albicans strains, suggesting that these EOs can be considered as possible therapeutic agents to control fungal pathogenicity. Patchouli and cinnamon EOs required at least 0.5% v/v (approximately 4500 µg/mL for our EOs) to effectively inhibit hyphae formation on C. albicans [33].
Non-active EOs against Candida strains could present other biological activities as shown for S. aspera (insecticide), Piper spp. (antioxidant and antimicrobial), Ocimum spp. (anti-inflammatory), Pogostemon spp., H. carinosum (antibacterial), and Turnera diffusa (cytotoxic activity) [18,50,51,52]. However, the biological activities of EOs derived from plants such E. quinquenervis, H. dilatata, S. viminea, A. popayanensis, Simsia spp., and M. rhopaloides are scarce or almost non-existent in the literature.
Compared to previous studies, biofilm inhibitory and antifungal concentrations of L. origanoides EOs are lower than those reported previously for bacterial strains (MIC > 375 µg/mL and MBIC > 100 µg/mL for S. aureus, E. coli and S. epidermidis strains) [18,19]. The results obtained in this work demonstrated the EOs’ potential to control the planktonic growth and biofilm formation of different species of Candida. Consequently, the EOs distilled from the different chemotypes of L. origanoides showed consistent biological effects against the Candida strains, mainly dependent on the chemical composition and concentration of the main components. Compounds like thymol, thymyl methyl ether, carvacrol, γ-terpinene, and p-cymene have extensive research in the literature about their antimicrobial and cytotoxic properties. However, the specific action mechanisms of their antibiofilm, antifungal, and antivirulence activity against pathogenic Candida strains have yet to be fully assessed. Further studies could include the evaluation of the synergy with less evaluated metabolites like iso-menthone, trans-β-bergamotene, cis-β-ocimene, humulene epoxide II, and terpinen-4-ol.

4. Materials and Methods

4.1. Plant Material

All plants used in this work were grown and harvested from experimental plots in the National Center for Agroindustialization of Aromatic and Medicinal Tropical Plant Species (CENIVAM) at the Industrial University of Santander (UIS, Bucaramanga, Colombia). Taxonomic identification was performed at the Colombian National Herbarium (National University of Colombia, UN, Bogotá, Colombia) and at the UIS Herbarium.
The exsiccatae and plant vouchers were deposited in the UIS Herbarium. Plants were initially collected in the countryside, and then propagated and grown in the CENIVAM experimental plots under controlled conditions. The EOs were distilled from fresh plant material. The voucher numbers, codes, plant identification, and relative compositions are shown in Supplementary Data Table S1.

4.2. Essential Oils

The EOs were distilled and characterized as previously described [18,21]. In brief, EOs were obtained by microwave-assisted hydro-distillation (MWHD) immediately after harvesting the plant material. Plants (200 g) were suspended in water (300 mL) and placed in a 2 L balloon connected to a Clevenger-type glass equipment with a Dean–Stark distillation reservoir. The plant sample was heated by microwave irradiation for 45 min (3 × 15 consecutive minutes). The EOs obtained were dried with anhydrous sodium sulfate, weighed, and stored in an amber bottle at 4 °C until further analysis. All distillations were performed in triplicate. The EOs were chemically characterized by GC/MS analysis as previously described, using a GC 6890 Plus gas chromatograph (Agilent Technologies, AT, Palo Alto, CA, USA) equipped with a mass selective detector MS 5973 Network (Palo Alto, CA, USA) using electron ionization (EI, 70 eV) [19].
For all biological tests, a stock solution (300 mg/mL) of each EO was prepared in dimethyl sulfoxide (DMSO, 100%), Sigma-Aldrich, St. Louis, MO, USA.

4.3. Microorganisms

The Candida species used in this study were Candida albicans ATCC 10231, C. auris CDC B11903, and C. parapsilosis ATCC 22019. These strains were stored in Sabouraud dextrose broth (SDB Sigma-Aldrich, St. Louis, MO, USA) with 20% (v/v) glycerol at −70 ± 5 °C until needed. Cells were reactivated and maintained in SDB and sabouraud dextrose agar (SDA) at 35 ± 2 °C for 48 h before each assay.

4.4. Determination of Antifungal Activity of EOs

Antifungal activities of the EOs were carried out by the broth microdilution method as described in the M27-A2 standard of the Clinical and Laboratory Standards Institute (CLSI) and standards of the European Committee for Antimicrobial Susceptibility Testing (EUCAST) with some modifications [53,54]. Initial screenings were performed to select EOs with antifungal activity at a concentration of 750 µg/mL prior to further evaluation. For screening, the EOs were prepared at 1500 µg/mL in sterile saline from the stock solution (300 mg/mL) dissolved in DMSO (100%; Sigma-Aldrich, St. Louis, MO, USA). After the screening, the EOs with antifungal activity were tested at 188, 281, 375, 563, and 750 µg/mL to determine their minimal inhibitory concentration (MIC50) and minimal fungicidal concentration (MFC) for each strain. The MIC50 is defined as the minimum concentration of EO being able to inhibit at least 50% of yeast growth compared to the control. The assays were performed with an initial inoculum of 0.5–5 × 105 CFU/mL in 2X RPMI 1640-MOPS (Sigma-Aldrich, St. Louis, MO, USA) mixed 1:1 with 100 µL of the respective EO adjusted to achieve the concentrations described above. Candida without EO, with DMSO (1%; Sigma-Aldrich, St. Louis, MO, USA), and fluconazole were used as the growth control, positive, and negative, respectively. Each 96-well microtiter plate (SPL, Gyeonggi-do, Korea) with the assay was incubated at 35 ± 2 °C in the dark and read at 530 nm by a Multiskan SkyHigh Microplate Spectrophotometer (Thermo Fisher-Scientific, Waltham, MA, USA) after 0, 24, and 48 h. Experiments were carried out in triplicate. The MFC was determined by plating 10 µL of the wells without growth on SDA. After 48 h of incubation at 35 ± 2 °C, the MFC, defined as the lowest concentration of compounds that killed at least 99.9% of the original inoculum compared to the untreated control, was determined.

4.5. Effect of EOs on Biofilm Formation

The potential of EOs to prevent biofilm formation of C. albicans ATCC 10231, C. auris CDC B11903, and C. parapsilosis ATCC 22019 was evaluated in sterile 96-well round-bottom microtiter plates (SPL, Pocheon-si, Korea) [55]. The biofilm formation tests were performed using EO solutions prepared at subinhibitory concentrations (<MIC50) from 47 to 750 µg/mL in saline. A fresh inoculum of 5–10 × 106 CFU/mL of C. albicans ATCC 10231, and C. auris CDC B11903 was prepared in 2X RPMI 1640-MOPS supplemented with glucose 2% (Merck KGaA, Darmstadt, Germany). For C. parapsilosis ATCC 22019, the inoculum was prepared in 2X SDB supplemented with glucose 2% at the same concentration. One hundred microliters of the respective inoculum was transferred into the plate with 100 µL of the respective EOs adjusted to achieve the concentrations described above. The plates were incubated for 24 h at 35 ± 2 °C in the dark. Cultures without EO were used as biofilm formation controls. After incubation, non-adherent cells were washed three times (3×) with sterile phosphate buffer saline (PBS pH 7.2). Biofilm formation was quantified by staining the wells with crystal violet (0.4% w/v) for 15 min. Then, the samples were washed with sterile saline to remove the excess dye, and 200 µL of 30% glacial acetic acid was added to each well [56]. Absorbance values at 590 nm were measured on a Multiskan SkyHigh Microplate Spectrophotometer (Thermo-Fisher Scientific, Waltham, MA, USA). The minimum biofilm inhibitory concentration (MBIC50) is defined as the minimum concentration of EO that can inhibit biofilm formation by at least 50% [18,19].

4.6. Scanning Electron Microscope Analysis

Scanning electron microscopy (SEM) was carried out to observe possible modifications in the C. auris adhesion and biofilm formation after treatment with EOs. LOT-I and LOT-II were evaluated at 94 and 144 µg/mL. Frosted glass coupons (1 cm × 2 cm × 5 mm) were deposited in 20 mL glass tubes with 2000 µL of an inoculum of 5–10 × 106 CFU/mL C. auris CDC B11903 and 2000 µL of the EO. After 24 h of incubation at 35 ± 2 °C in the dark, the coupons were gently washed three times with a saline solution to remove planktonic cells. Samples were fixed with 2.5% glutaraldehyde for 60 min and dehydrated with an isopropanol gradient (10, 20, 30, 40, 50, 60, 70, 80, and 100%) for 10 min [18,19]. The Samples were coated with gold and observed with a scanning electron microscope FEG (field emission gun) QUANTA FEG 650 (SEM, Thermo-Fisher Scientific, Waltham, MA, USA), equipped with an Everhart Thornley ETD detector.

4.7. Inhibition of Hyphal Formation in C. albicans by EOs

The effect of the EO on the ability of C. albicans ATCC 10231 to form hyphae was determined in 96-well microtiter plates. Briefly, the cell suspension was diluted to 5–10 × 106 CFU/mL in 200 µL of RPMI 1640 supplemented with 10% fetal bovine serum (FBS, Invitrogen) that contained different concentrations (47–375 µg/mL) of EO or 1% DMSO. The plate was incubated at 37 ± 2 °C with agitation (200 rpm) for 5 h and visualized using 40× lens brightfield Zeiss microscope. The photographs were taken with a Zeiss Axiocam 208 color camera [57,58].

4.8. Data Analysis

All the experiments were carried out in triplicate. All results were expressed as the means and their respective standard deviations for each assay. All statistical analyses were performed on Prisma, and a p < 0.05 was considered statistically significant. Significant changes are indicated by an asterisk in the figures. The assumption of normality and equality of variances of data were previously tested using Shapiro–Wilk and Levene test, respectively. Spearman’s correlation test was done to assess the relationships between antifungal and antibiofilm activities. The correlation coefficient can be positive (directly proportional) or negative (inversely proportional), and quantitative values suggest that the relationship between two or more variables is strong, moderate, or weak: 0.00 to 0.19 (very weak); 0.20 to 0.39 (weak); 0.40 to 0.69 (moderate); 0.70 to 0.89 (strong) and 0.90 to 1.00 (very strong) [59].

5. Conclusions

To summarize, this research shows that Colombian EOs present antifungal and antibiofilm properties from mainly those that contained high contents of secondary metabolites, such as carvacrol, thymol, thymyl methyl ether, γ-terpinene, and p-cymene. In this study, we demonstrated the potential of EOs from L. origanoides, L. alba, and M. mollis to inhibit planktonic and sessile growth of different Candida species. Additionally, partial inhibition of hyphal production was demonstrated. These results open the possibility for their use in the design of new therapeutic strategies against Candida spp.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/antibiotics12040668/s1, Table S1. List of Colombian EOs assessed in this study. Major chemical compounds identified, and their relative amounts reported as a percentage (%); Table S2. Bioactive and non-bioactive Colombian EOs major chemical compounds identified. Data is organized by bioactive properties; Table S3. MIC50 and MFC values for the EOs studied against C. albicans, C. parapsilosis, and C. auris; Table S4. MBIC50 values for the EOs studied against C. albicans, C. parapsilosis, and C. auris; Table S5. Spearman’s correlation analysis between antifungal activities (MIC) against Candida strains vs. identified compounds in the Colombian EOs; Table S6. Spearman’s correlation analysis between antifungal activities (MBIC) against Candida strains vs. identified compounds in the Colombian EOs.

Author Contributions

Conceptualization, J.R.-D. and C.O.; methodology, J.R.-D. and C.O.; validation, R.T., E.E.S. and C.O.; formal analysis, J.R.-D.; investigation, J.R.-D.; resources, E.E.S. and C.O.; data curation, J.R.-D.; writing—original draft preparation, J.R.-D. and C.O.; writing—review and editing, R.T., E.E.S. and C.O.; visualization, J.R.-D.; supervision, E.E.S. and C.O.; project administration, E.E.S. and C.O.; funding acquisition, E.E.S. and C.O. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by Ministerio de Ciencia, Tecnología e Innovación, Ministerio de Educación Nacional, Ministerio de Industria, Comercio y Turismo, and ICETEX, Program Ecosistema Científico-Colombia Científica from Fondo Francisco José de Caldas; Grant RC-FP44842-212-2018.

Institutional Review Board Statement

The Ministry of Environment and Sustainable Development of Colombia supported the Universidad Industrial de Santander through the permit to genetic resources and derivatives access of bioprospecting (Contract N° 270). Project RC-FP44842-212-2018 was approved by the Scientific Research Ethical Committee (Record N° 15-2017, File N° 4110) from Universidad Industrial de Santander. The experiments and the chemical management were done according to national law (Resolution N° 008430-1993) from the Ministry of Health of Colombia and the Institutional Manual of Integrated Management and Processes (PGOR-PGGA.05).

Informed Consent Statement

Not applicable.

Data Availability Statement

Data are contained within the article or Supplementary Materials.

Acknowledgments

The authors thank funding from the Ministry of Science, Technology and Innovation, the Ministry of Education, the Ministry of Industry, Commerce and Tourism, and ICETEX, Programme Ecosistema Científico-Colombia Científica, from the Francisco José de Caldas Fund, Grand RC-FP44842-212-2018.

Conflicts of Interest

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

References

  1. Guinea, J. Global Trends in the Distribution of Candida Species Causing Candidemia. Clin. Microbiol. Infect. 2014, 20, 5–10. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  2. CDC Antibiotic Resistance Threats in the United States, 2019; Centers for Disease Control and Prevention: Atlanta, GA, USA, 2019.
  3. Fan, F.; Liu, Y.; Liu, Y.; Lv, R.; Sun, W.; Ding, W.; Cai, Y.; Li, W.; Liu, X.; Qu, W. Candida albicans Biofilms: Antifungal Resistance, Immune Evasion, and Emerging Therapeutic Strategies. Int. J. Antimicrob. Agents 2022, 60, 106673. [Google Scholar] [CrossRef]
  4. World Health Organization (WHO). WHO Fungal Priority Pathogens List to Guide Research, Development and Public Health Action; WHO: Geneva, Switzerland, 2022. [Google Scholar]
  5. del Pozo, J.L. Biofilm-Related Disease. Expert Rev. Anti-Infect. Ther. 2018, 16, 51–65. [Google Scholar] [CrossRef] [PubMed]
  6. Tumbarello, M.; Posteraro, B.; Trecarichi, E.M.; Fiori, B.; Rossi, M.; Porta, R.; de Gaetano Donati, K.; la Sorda, M.; Spanu, T.; Fadda, G.; et al. Biofilm Production by Candida Species and Inadequate Antifungal Therapy as Predictors of Mortality for Patients with Candidemia. J. Clin. Microbiol. 2007, 45, 1843–1850. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  7. Dominguez, E.G.; Andes, D.R. Candida Biofilm Tolerance: Comparison of Planktonic and Biofilm Resistance Mechanisms. In Candida albicans: Cellular and Molecular Biology; Springer International Publishing: Cham, Switzerland, 2017; pp. 77–92. [Google Scholar]
  8. Chen, H.; Zhou, X.; Ren, B.; Cheng, L. The Regulation of Hyphae Growth in Candida albicans. Virulence 2020, 11, 337–348. [Google Scholar] [CrossRef] [Green Version]
  9. Silva, S.; Negri, M.; Henriques, M.; Oliveira, R.; Williams, D.W.; Azeredo, J. Adherence and Biofilm Formation of Non-Candida albicans Candida Species. Trends Microbiol. 2011, 19, 241–247. [Google Scholar] [CrossRef] [Green Version]
  10. Powers, C.; Osier, J.; McFeeters, R.; Brazell, C.; Olsen, E.; Moriarity, D.; Satyal, P.; Setzer, W. Antifungal and Cytotoxic Activities of Sixty Commercially-Available Essential Oils. Molecules 2018, 23, 1549. [Google Scholar] [CrossRef] [Green Version]
  11. Ribeiro, R.; Fernandes, L.; Costa, R.; Cavaleiro, C.; Salgueiro, L.; Henriques, M.; Rodrigues, M.E. Comparing the Effect of Thymus spp. Essential Oils on Candida auris. Ind. Crops Prod. 2022, 178, 114667. [Google Scholar] [CrossRef]
  12. Córdoba, S.; Vivot, W.; Szusz, W.; Albo, G. Antifungal Activity of Essential Oils Against Candida Species Isolated from Clinical Samples. Mycopathologia 2019, 184, 615–623. [Google Scholar] [CrossRef]
  13. Imane, N.I.; Fouzia, H.; Azzahra, L.F.; Ahmed, E.; Ismail, G.; Idrissa, D.; Mohamed, K.H.; Sirine, F.; L’Houcine, O.; Noureddine, B. Chemical Composition, Antibacterial and Antioxidant Activities of Some Essential Oils against Multidrug Resistant Bacteria. Eur. J. Integr. Med. 2020, 35, 101074. [Google Scholar] [CrossRef]
  14. Sounouvou, H.T.; Toukourou, H.; Catteau, L.; Toukourou, F.; Evrard, B.; van Bambeke, F.; Gbaguidi, F.; Quetin-Leclercq, J. Antimicrobial Potentials of Essential Oils Extracted from West African Aromatic Plants on Common Skin Infections. Sci. Afr. 2021, 11, e00706. [Google Scholar] [CrossRef]
  15. Sobrinho, A.C.N.; de Souza, E.B.; Rocha, M.F.G.; Albuquerque, M.R.J.R.; Bandeira, P.N.; dos Santos, H.S.; de Paula Cavalcante, C.S.; Oliveira, S.S.; Aragão, P.R.; de Morais, S.M.; et al. Chemical Composition, Antioxidant, Antifungal and Hemolytic Activities of Essential Oil from Baccharis trinervis (Lam.) Pers. (Asteraceae). Ind. Crops Prod. 2016, 84, 108–115. [Google Scholar] [CrossRef]
  16. Nazzaro, F.; Fratianni, F.; Coppola, R.; de Feo, V. Essential Oils and Antifungal Activity. Pharmaceuticals 2017, 10, 86. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  17. Stashenko, E.; René Martínez, J. Study of Essential Oils Obtained from Tropical Plants Grown in Colombia. In Essential Oils—Oils of Nature; IntechOpen: London, UK, 2020. [Google Scholar]
  18. Cáceres, M.; Hidalgo, W.; Stashenko, E.; Torres, R.; Ortiz, C. Essential Oils of Aromatic Plants with Antibacterial, Anti-Biofilm and Anti-Quorum Sensing Activities against Pathogenic Bacteria. Antibiotics 2020, 9, 147. [Google Scholar] [CrossRef] [Green Version]
  19. Gómez-Sequeda, N.; Cáceres, M.; Stashenko, E.E.; Hidalgo, W.; Ortiz, C. Antimicrobial and Antibiofilm Activities of Essential Oils against Escherichia coli O157:H7 and Methicillin-Resistant Staphylococcus aureus (MRSA). Antibiotics 2020, 9, 730. [Google Scholar] [CrossRef] [PubMed]
  20. Martínez, A.; Manrique-Moreno, M.; Klaiss-Luna, M.C.; Stashenko, E.; Zafra, G.; Ortiz, C. Effect of Essential Oils on Growth Inhibition, Biofilm Formation and Membrane Integrity of Escherichia coli and Staphylococcus aureus. Antibiotics 2021, 10, 1474. [Google Scholar] [CrossRef]
  21. Zapata-Zapata, C.; Loaiza-Oliva, M.; Martínez-Pabón, M.C.; Stashenko, E.E.; Mesa-Arango, A.C. In Vitro Activity of Essential Oils Distilled from Colombian Plants against Candida auris and Other Candida Species with Different Antifungal Susceptibility Profiles. Molecules 2022, 27, 6837. [Google Scholar] [CrossRef]
  22. Ambrosio, C.M.S.; Ikeda, N.Y.; Miano, A.C.; Saldaña, E.; Moreno, A.M.; Stashenko, E.; Contreras-Castillo, C.J.; da Gloria, E.M. Unraveling the Selective Antibacterial Activity and Chemical Composition of Citrus Essential Oils. Sci. Rep. 2019, 9, 17719. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  23. Arendrup, M.C.; Patterson, T.F. Multidrug-Resistant Candida: Epidemiology, Molecular Mechanisms, and Treatment. J. Infect. Dis. 2017, 216, S445–S451. [Google Scholar] [CrossRef] [Green Version]
  24. Macias-Paz, I.U.; Pérez-Hernández, S.; Tavera-Tapia, A.; Luna-Arias, J.P.; Guerra-Cárdenas, J.E.; Reyna-Beltrán, E. Candida albicans the Main Opportunistic Pathogenic Fungus in Humans. Rev. Argent. Microbiol. 2022, in press. [Google Scholar] [CrossRef]
  25. Tsui, C.; Kong, E.F.; Jabra-Rizk, M.A. Pathogenesis of Candida albicans Biofilm. Pathog. Dis. 2016, 74, ftw018. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  26. Panáček, A.; Kolář, M.; Večeřová, R.; Prucek, R.; Soukupová, J.; Kryštof, V.; Hamal, P.; Zbořil, R.; Kvítek, L. Antifungal Activity of Silver Nanoparticles against Candida spp. Biomaterials 2009, 30, 6333–6340. [Google Scholar] [CrossRef] [PubMed]
  27. Zottich, U.; de Oliveira, I.S.; Fereira, I.G.; Cerni, F.A.; Karla de Castro Figueiredo, B.; Arantes, E.C.; Gomes, V.M.; Dias, G.B.; Pucca, M.B. Antifungal Activity of Rhopalurus crassicauda Venom against Candida spp. Toxicon X 2022, 14, 100120. [Google Scholar] [CrossRef] [PubMed]
  28. Sebaa, S.; Boucherit-Otmani, Z.; Courtois, P. Effects of Tyrosol and Farnesol on Candida albicans Biofilm. Mol. Med. Rep. 2019, 19, 3201–3209. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  29. Lee, J.H.; Kim, Y.G.; Lee, J.H. Inhibition of Candida albicans Biofilm and Hyphae Formation by Biocompatible Oligomers. Lett. Appl. Microbiol. 2018, 67, 123–129. [Google Scholar] [CrossRef] [PubMed]
  30. Patel, M.; Srivastava, V.; Ahmad, A. Dodonaea Viscosa Var Angustifolia Derived 5,6,8-Trihydroxy-7,4′ Dimethoxy Flavone Inhibits Ergosterol Synthesis and the Production of Hyphae and Biofilm in Candida albicans. J. Ethnopharmacol. 2020, 259, 112965. [Google Scholar] [CrossRef]
  31. Mangalagiri, N.P.; Panditi, S.K.; Jeevigunta, N.L.L. Antimicrobial Activity of Essential Plant Oils and Their Major Components. Heliyon 2021, 7, e06835. [Google Scholar] [CrossRef]
  32. Puvača, N.; Milenković, J.; Galonja Coghill, T.; Bursić, V.; Petrović, A.; Tanasković, S.; Pelić, M.; Ljubojević Pelić, D.; Miljković, T. Antimicrobial Activity of Selected Essential Oils against Selected Pathogenic Bacteria: In Vitro Study. Antibiotics 2021, 10, 546. [Google Scholar] [CrossRef]
  33. Farisa Banu, S.; Rubini, D.; Shanmugavelan, P.; Murugan, R.; Gowrishankar, S.; Karutha Pandian, S.; Nithyanand, P. Effects of Patchouli and Cinnamon Essential Oils on Biofilm and Hyphae Formation by Candida Species. J. Mycol. Med. 2018, 28, 332–339. [Google Scholar] [CrossRef]
  34. Barbiéri Holetz, F.; Lorena Pessini, G.; Rogério Sanches, N.; Aparício Garcia Cortez, D.; Vataru Nakamura, C.; Prado Dias Filho, B. Screening of Some Plants Used in the Brazilian Folk Medicine for the Treatment of Infectious Diseases. Mem. Inst. Oswaldo Cruz 2002, 97, 1027–1031. [Google Scholar] [CrossRef] [Green Version]
  35. León-Méndez, G.; Pájaro-Castro, N.; Pájaro-Castro, E.; Torrenegra- Alarcón, M.; Herrera-Barros, A. Essential Oils as a Source of Bioactive Molecules. Rev. Colomb. Cienc. Químico-Farm. 2019, 48, 80–93. [Google Scholar] [CrossRef] [Green Version]
  36. Nostro, A.; Roccaro, A.S.; Bisignano, G.; Marino, A.; Cannatelli, M.A.; Pizzimenti, F.C.; Cioni, P.L.; Procopio, F.; Blanco, A.R. Effects of Oregano, Carvacrol and Thymol on Staphylococcus aureus and Staphylococcus epidermidis Biofilms. J. Med. Microbiol. 2007, 56, 519–523. [Google Scholar] [CrossRef]
  37. Jafri, H.; Ahmad, I. Thymus vulgaris Essential Oil and Thymol Inhibit Biofilms and Interact Synergistically with Antifungal Drugs against Drug Resistant Strains of Candida albicans and Candida tropicalis. J. Mycol. Med. 2020, 30, 100911. [Google Scholar] [CrossRef]
  38. Belato, K.K.; de Oliveira, J.R.; de Oliveira, F.S.; de Oliveira, L.D.; Camargo, S.E.A. Cytotoxicity and Genotoxicity of Thymol Verified in Murine Macrophages (RAW 264.7) after Antimicrobial Analysis in Candida albicans, Staphylococcus aureus, and Streptococcus mutans. J. Funct. Foods 2018, 40, 455–460. [Google Scholar] [CrossRef] [Green Version]
  39. Miladi, H.; Zmantar, T.; Kouidhi, B.; al Qurashi, Y.M.A.; Bakhrouf, A.; Chaabouni, Y.; Mahdouani, K.; Chaieb, K. Synergistic Effect of Eugenol, Carvacrol, Thymol, p-Cymene and γ-Terpinene on Inhibition of Drug Resistance and Biofilm Formation of Oral Bacteria. Microb. Pathog. 2017, 112, 156–163. [Google Scholar] [CrossRef]
  40. Rathod, N.B.; Kulawik, P.; Ozogul, F.; Regenstein, J.M.; Ozogul, Y. Biological Activity of Plant-Based Carvacrol and Thymol and Their Impact on Human Health and Food Quality. Trends Food Sci. Technol. 2021, 116, 733–748. [Google Scholar] [CrossRef]
  41. Balahbib, A.; el Omari, N.; el Hachlafi, N.; Lakhdar, F.; el Menyiy, N.; Salhi, N.; Mrabti, H.N.; Bakrim, S.; Zengin, G.; Bouyahya, A. Health Beneficial and Pharmacological Properties of P-Cymene. Food Chem. Toxicol. 2021, 153, 112259. [Google Scholar] [CrossRef]
  42. Vasconcelos, S.E.C.B.; Melo, H.M.; Cavalcante, T.T.A.; Júnior, F.E.A.C.; de Carvalho, M.G.; Menezes, F.G.R.; de Sousa, O.V.; Costa, R.A. Plectranthus Amboinicus Essential Oil and Carvacrol Bioactive against Planktonic and Biofilm of Oxacillin- and Vancomycin-Resistant Staphylococcus Aureus. BMC Complement. Altern. Med. 2017, 17, 462. [Google Scholar] [CrossRef] [Green Version]
  43. Gucwa, K.; Milewski, S.; Dymerski, T.; Szweda, P. Investigation of the Antifungal Activity and Mode of Action of Thymus vulgaris, Citrus limonum, Pelargonium graveolens, Cinnamomum cassia, Ocimum basilicum, and Eugenia caryophyllus Essential Oils. Molecules 2018, 23, 1116. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. Karpiński, T.M.; Ożarowski, M.; Seremak-Mrozikiewicz, A.; Wolski, H.; Adamczak, A. Plant Preparations and Compounds with Activities against Biofilms Formed by Candida spp. J. Fungi 2021, 7, 360. [Google Scholar] [CrossRef] [PubMed]
  45. Fernandes, L.; Ribeiro, R.; Costa, R.; Henriques, M.; Rodrigues, M.E. Essential Oils as a Good Weapon against Drug-Resistant Candida auris. Antibiotics 2022, 11, 977. [Google Scholar] [CrossRef] [PubMed]
  46. Parker, R.A.; Gabriel, K.T.; Graham, K.D.; Butts, B.K.; Cornelison, C.T. Antifungal Activity of Select Essential Oils against Candida auris and Their Interactions with Antifungal Drugs. Pathogens 2022, 11, 821. [Google Scholar] [CrossRef]
  47. Choonharuangdej, S.; Srithavaj, T.; Thummawanit, S. Fungicidal and Inhibitory Efficacy of Cinnamon and Lemongrass Essential Oils on Candida albicans Biofilm Established on Acrylic Resin: An In Vitro Study. J. Prosthet. Dent. 2021, 125, 707.e1–707.e6. [Google Scholar] [CrossRef]
  48. Jackson, S.; Coulthwaite, L.; Loewy, Z.; Scallan, A.; Verran, J. Biofilm Development by Blastospores and Hyphae of Candida albicans on Abraded Denture Acrylic Resin Surfaces. J. Prosthet. Dent. 2014, 112, 988–993. [Google Scholar] [CrossRef]
  49. Agarwalla, S.V.; Ellepola, K.; Silikas, N.; Castro Neto, A.H.; Seneviratne, C.J.; Rosa, V. Persistent Inhibition of Candida albicans Biofilm and Hyphae Growth on Titanium by Graphene Nanocoating. Dent. Mater. 2021, 37, 370–377. [Google Scholar] [CrossRef] [PubMed]
  50. Duque, J.E.; Urbina, D.L.; Vesga, L.C.; Ortiz-Rodríguez, L.A.; Vanegas, T.S.; Stashenko, E.E.; Mendez-Sanchez, S.C. Insecticidal Activity of Essential Oils from American Native Plants against Aedes Aegypti (Diptera: Culicidae): An Introduction to Their Possible Mechanism of Action. Sci. Rep. 2023, 13, 2989. [Google Scholar] [CrossRef] [PubMed]
  51. Shirazi, M.T.; Gholami, H.; Kavoosi, G.; Rowshan, V.; Tafsiry, A. Chemical Composition, Antioxidant, Antimicrobial and Cytotoxic Activities of Tagetes minuta and Ocimum basilicum Essential Oils. Food Sci. Nutr. 2014, 2, 146–155. [Google Scholar] [CrossRef]
  52. Chen, Y.; Luo, Q.; Li, S.; Li, C.; Liao, S.; Yang, X.; Zhou, R.; Zhu, Y.; Teng, L.; Chen, H.; et al. Antiviral Activity against Porcine Epidemic Diarrhea Virus of Pogostemon cablin Polysaccharide. J. Ethnopharmacol. 2020, 259, 113009. [Google Scholar] [CrossRef]
  53. M27-A2-CLSI; Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. Clinical Laboratory Standards Institute: Berwyn, PA, USA, 2002.
  54. Arendrup, M.C.; Meletiadis, J.; Mouton, J.W.; Lagrou, K.; Hamal, P.; Guinea, J. EUCAST-AFST Method for the Determination of Broth Dilution Minimum Inhibitory Concentrations of Antifungal Agents for Yeasts. In EUCAST Antifungal MIC Method for Yeasts; V 7.3.2; EUCAST: Copenhagen, Denmark, 2020; pp. 1–21. Available online: https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/AFST/Files/EUCAST_E_Def_7.3.2_Yeast_testing_definitive_revised_2020.pdf (accessed on 23 February 2023).
  55. Pierce, C.G.; Uppuluri, P.; Tristan, A.R.; Wormley, F.L.; Mowat, E.; Ramage, G.; Lopez-Ribot, J.L. A Simple and Reproducible 96-Well Plate-Based Method for the Formation of Fungal Biofilms and Its Application to Antifungal Susceptibility Testing. Nat. Protoc. 2008, 3, 1494–1500. [Google Scholar] [CrossRef]
  56. O’Toole, G.A. Microtiter Dish Biofilm Formation Assay. J. Vis. Exp. 2011, e2437. [Google Scholar] [CrossRef]
  57. Haque, F.; Alfatah, M.; Ganesan, K.; Bhattacharyya, M.S. Inhibitory Effect of Sophorolipid on Candida albicans Biofilm Formation and Hyphal Growth. Sci. Rep. 2016, 6, 23575. [Google Scholar] [CrossRef] [Green Version]
  58. Tsang, P.W.K.; Bandara, H.M.H.N.; Fong, W.P. Purpurin Suppresses Candida albicans Biofilm Formation and Hyphal Development. PLoS ONE 2012, 7, e50866. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  59. Akoglu, H. User’s Guide to Correlation Coefficients. Turk. J. Emerg. Med. 2018, 18, 91–93. [Google Scholar] [CrossRef] [PubMed]
Antibiotics 12 00668 g001 550
Figure 1. Screening of antifungal activity of 50 EOs (750 µg/mL) against (A) C. albicans ATCC 10231, (B) C. parapsilosis ATCC 22019, and (C) C. auris CDC B11903 after 48 h of treatment.
Figure 1. Screening of antifungal activity of 50 EOs (750 µg/mL) against (A) C. albicans ATCC 10231, (B) C. parapsilosis ATCC 22019, and (C) C. auris CDC B11903 after 48 h of treatment.
Antibiotics 12 00668 g001
Antibiotics 12 00668 g002 550
Figure 2. Effect of antifungal EO LOT-I (L. origanoides, thymol chemotype) and LOT-II (L. origanoides, thymol chemotype) on biofilm formation of C. albicans ATCC 10231 (A,B), C. auris CDC B11903 (C,D), and C. parapsilosis ATCC 22019 (E,F). Letters denote a significant difference between the treated and untreated controls, based on Tukey’s test (ns: p > 0.05 b: p ≤ 0.01; c: p ≤ 0.001; d: p ≤ 0.0001).
Figure 2. Effect of antifungal EO LOT-I (L. origanoides, thymol chemotype) and LOT-II (L. origanoides, thymol chemotype) on biofilm formation of C. albicans ATCC 10231 (A,B), C. auris CDC B11903 (C,D), and C. parapsilosis ATCC 22019 (E,F). Letters denote a significant difference between the treated and untreated controls, based on Tukey’s test (ns: p > 0.05 b: p ≤ 0.01; c: p ≤ 0.001; d: p ≤ 0.0001).
Antibiotics 12 00668 g002
Antibiotics 12 00668 g003 550
Figure 3. SEM images of C. auris biofilm (A) untreated (Control) (B) Treated with 53 µg/mL of LOT-I: and (C) Treated with 141 µg/mL of EO LOT-II. SEM images were recorded at 2000 and 5000, and 10,000× magnification, respectively.
Figure 3. SEM images of C. auris biofilm (A) untreated (Control) (B) Treated with 53 µg/mL of LOT-I: and (C) Treated with 141 µg/mL of EO LOT-II. SEM images were recorded at 2000 and 5000, and 10,000× magnification, respectively.
Antibiotics 12 00668 g003
Antibiotics 12 00668 g004 550
Figure 4. Effects of LOC, LOT-I, LOTC, LOT-II, LACL and MM-II on hyphal growth of C. albicans in liquid media. Yeasts were grown in RPMI 1640 medium with 10% SFB and photographed at 40× magnification after 6 h incubation.
Figure 4. Effects of LOC, LOT-I, LOTC, LOT-II, LACL and MM-II on hyphal growth of C. albicans in liquid media. Yeasts were grown in RPMI 1640 medium with 10% SFB and photographed at 40× magnification after 6 h incubation.
Antibiotics 12 00668 g004
Table
Table 1. Information on the plants and chemical composition of EOs with biological activity (antifungal or antibiofilm) against at least one of the Candida strains.
Table 1. Information on the plants and chemical composition of EOs with biological activity (antifungal or antibiofilm) against at least one of the Candida strains.
Plant CodePlant SpeciesVouche
Number		Major EO Compounds
TD-ITurnera diffusaUIS Herbarium 22037Dehydrofukinone (25.4%), aristolochene (17.9%), valencene (7.4%), β-selinene (5.2%), trans-β-caryophyllene (4.0%), β-elemene (4.0%), premnaspirodiene (3.7%), guaiol (3.5%), germacra-4,5,10-trien-1-α-ol (3.5%), and caryophyllene oxide (3.3%).
EQElaphandra quinquenervisCOL 587094Germacrene D (20.7%), α-phellandrene (9.1%), α-pinene (6.8%), trans-β-caryophyllene (5.1%), Δ3-carene (4.9%), limonene (4.5%), β-cubebene (3.5%), α-humulene (2.6%), premnaspirodiene (2.6%), and δ-cadinene (2.6%).
LOCLippia origanoides,
carvacrol chemotype		UIS Herbarium 22034Carvacrol (35%), p-cymene (14.4%), thymol (8.0%), γ-terpinene (5.3%), trans-β-caryophyllene (4.4%), β-myrcene (2.4%), carvacryl acetate (2.0%), thymyl methyl ether (1.9%), and α-terpinene (1.7%).
LOCpTLippia origanoides,
β-Caryophyllene-thymol chemotype		UIS Herbarium 22035trans-β-Caryophyllene (15.1%), thymol (14%), 1,8-cineole (13%), p-cymene (12.6%), α-humulene (8.1%), α-phellandrene (7.1%), α-eudesmol (2.6%), caryophyllene oxide (2.5%), γ-terpinene (2.4%), and limonene (2.1%).
LOT-ILippia origanoides,
thymol chemotype		COL 587107Thymol (75.3%), trans-β-caryophyllene (5.4%), carvacrol (4.9%), α-humulene (3.2%), p-cymene (2.3%), thymyl acetate (1.6%), thymyl methyl ether (1.3%), caryophyllene oxide (1.3%), and trans-β-bergamotene (1.0%).
TD-IIITurnera diffusaHerbarium UIS 22037Aristolochene (20.6%), dehydrofukinone (17.3%), p-cymene (5.8%), β-selinene (5.6%), valencene (5.2%), premnaspirodiene (4.2%), caryophyllene oxide (3.6%), trans-β-caryophyllene (2.8%), germacra-4,5,10-trien-1-α-ol (2.4%), and α-selinene.
LOTCLippia origanoides,
thymol-p-cymene chemotype		Herbarium UIS 22039Thymol (49.4%), p-cymene (19.1%), γ-terpinene (9.2%), β-myrcene (5.2%), α-terpinene (2.9%), carvacrol (2.7%), thymyl methyl ether (1.8%), trans-β-caryophyllene (1.6%), cis-β-ocimene (1.2%), and limonene (0.9%).
LOT-IILippia origanoides,
thymol chemotype		Herbarium UIS 22036Thymol (71.7%), p-cymene (10.5%), carvacrol (4.4%), β-myrcene (2.1%), γ-terpinene (2.0%), caryophyllene oxide (1.6%), thymyl methyl ether (0.9%), trans-β-caryophyllene (0.9%), humulene epoxide II (0.7%), and terpinen-4-ol (0.7%).
LMLippia micromeraCOL 560986p-Cymene (26.8%), thymyl methyl ether (26.3%), thymol (17.8%), thymyl acetate (5.7%), γ-terpinene (5.4%), 1,8-cineole (5.1%), α-terpinene (2.0%), β-myrcene (2.0%), trans-β-caryophyllene (1.7%), α-thujene (1.3%), and caryophyllene oxide (0.9%).
OCOcimum campechianumUIS Herbarium 20889Eugenol (35.3%), 1,8-cineole (15.6%), β-selinene (11.0%), trans-β-caryophyllene (7.4%), germacrene D (5.6%), α-selinene (4.8%), β-pinene (2.4%), β-elemene (1.9%), and α-humulene (1.5%).
LACLLippia alba,
carvone-limonene chemotype		UIS Herbarium 22031Limonene (40.1%), carvone (37.7%), germacrene D (8.1%), β-bourbonene (3.0%), piperitone (1.9%), β-myrcene (0.9%), piperitenone (0.8%), linalool (0.7%), borneol (0.7%), and trans-β-farnesene (0.7%).
LACiLippia alba,
citral chemotype 		UIS Herbarium 22032Geranial (24.5%), geraniol (19.0%), neral (11.9%), trans-β-caryophyllene (9.1%), germacrene D (4.3%), geranyl acetate (2.8%), α-humulene (2.8%), β-elemene (2.6%), nerol (2.5%), and limonene (2.4%).
MM-IMinthostachys mollis (Benth.) Griseb.UIS Herbarium 22041trans-Piperitone oxide (49.6%), menthone (8.9%), piperitenone oxide (4.8%), trans-β-caryophyllene (4.0%), limonene (3.3%), thymol (2.3%), 6-hydroxycarvotanacetone (2.3%), germacrene D (2.1%), β-pinene (2.0%), linalool (1.9%), and pulegone (1.7%).
MM-IIMinthostachys mollis (Benth.) Griseb.UIS Herbarium 22042Menthone (46.1%), pulegone (13.3%), piperitone (12.1%), trans-β-caryophyllene (7.0%), germacrene D (3.8%), iso-menthone (3.5%), bicyclogermacrene (3.4%), α-humulene (1.9%), α-pinene (1.3%), and β-pinene (1.2%).
UIS: Industrial University of Santander (Bucaramanga, Colombia).
Table
Table 2. MIC50 and MFC values for the most active EOs studied against C. albicans ATCC 10231, C. parapsilosis ATCC 22019, and C. auris CDC B11903 after 48 h of culture.
Table 2. MIC50 and MFC values for the most active EOs studied against C. albicans ATCC 10231, C. parapsilosis ATCC 22019, and C. auris CDC B11903 after 48 h of culture.
EOC. albicans ATCC 10231C. parapsilosis ATCC 22019C. auris CDC B11903
MIC50
(µg/mL)		MFC
(µg/mL)		MIC50
(µg/mL)		MFC
(µg/mL)		MIC50
(µg/mL)		MFC
(µg/mL)
EQNANA375NANANA
LOC375NA281NA281NA
LOCpT563750188NA750NA
LOT-I281750188750188563
LOTC188NA281NA188375
LOT-II188563141563141375
LM750NA188NA750NA
OC563NA563NA563NA
LACL750NA750NA188563
LACi750NA750NA563NA
MM-I750NA375750375NA
HC563NA375750375NA
NA: non-active.
Table
Table 3. MBIC50 values for the most active EOs studied against C. albicans ATCC 10231, C. parapsilosis ATCC 22019, and C. auris CDC B11903 after 48 h of culture.
Table 3. MBIC50 values for the most active EOs studied against C. albicans ATCC 10231, C. parapsilosis ATCC 22019, and C. auris CDC B11903 after 48 h of culture.
Essential OilC. albicans ATCC 10231C. parapsilosis ATCC 22019C. auris CDC B11903
MBIC50
(µg/mL)		MBIC50
(µg/mL)		MBIC50
(µg/mL)
TD-INA750NA
LOC281188NA
LOCpT375281NA
LOT-I535353
CM-IINA750NA
TD-IIINA750NA
LOTC94141141
LOT-II188188141
LACLNA750NA
MM-IINANA188
NA: non-active.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Ruiz-Duran, J.; Torres, R.; Stashenko, E.E.; Ortiz, C. Antifungal and Antibiofilm Activity of Colombian Essential Oils against Different Candida Strains. Antibiotics 2023, 12, 668. https://doi.org/10.3390/antibiotics12040668

AMA Style

Ruiz-Duran J, Torres R, Stashenko EE, Ortiz C. Antifungal and Antibiofilm Activity of Colombian Essential Oils against Different Candida Strains. Antibiotics. 2023; 12(4):668. https://doi.org/10.3390/antibiotics12040668

Chicago/Turabian Style

Ruiz-Duran, Jennifer, Rodrigo Torres, Elena E. Stashenko, and Claudia Ortiz. 2023. "Antifungal and Antibiofilm Activity of Colombian Essential Oils against Different Candida Strains" Antibiotics 12, no. 4: 668. https://doi.org/10.3390/antibiotics12040668

APA Style

Ruiz-Duran, J., Torres, R., Stashenko, E. E., & Ortiz, C. (2023). Antifungal and Antibiofilm Activity of Colombian Essential Oils against Different Candida Strains. Antibiotics, 12(4), 668. https://doi.org/10.3390/antibiotics12040668

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop